Reactogenicity, Safety, and Serological and Cellular Immunogenicity of a Booster Dose of SARS-CoV-2 mRNA Prototype, Variant, and Bivalent Vaccines
Evan J. Anderson,Lisa A. Jackson,Nadine Rouphael,Alicia T. Widge,David C. Montefiori,Nicole A. Doria‐Rose,Mehul S. Suthar,Kristen W. Cohen,Sarah O’Connell,Mat Makowski,Mamodikoe Makhene,Wendy Buchanan,Paul Spearman,C. Buddy Creech,Sijy O’Dell,Stephen D. Schmidt,Brett Leav,Hamilton Bennett,Rolando Pajón,Christine M. Posavad,John Hural,John H Beigel,Jim Albert,Kuleni Abebe,Amanda Eaton,Christina A. Rostad,Paulina A. Rebolledo,Satoshi Kamidani,Daniel S. Graciaa,Rhea N. Coler,Adrian B. McDermott,Julie E. Ledgerwood,John R. Mascola,Stephen C. De Rosa,Kathleen M. Neuzil,M. Juliana McElrath,Paul C. Roberts Research Square (Research Square)（2022）
Key words
bivalent vaccines,cellular immunogenicity,booster dose,sars-cov
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper